Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Pfizer says earliest U.S. filing for COVID-19 vaccine would be late November

share with twitter share with LinkedIn share with facebook
10/16/2020 | 10:36pm EDT
FILE PHOTO: FILE PHOTO: A sign is pictured outside Pfizer Headquarters in the Manhattan borough of New York City

(Reuters) - Pfizer Inc said on Friday it could file in late November for U.S. authorization of the COVID-19 vaccine it is developing, suggesting that a vaccine could potentially be available in the United States by the end of the year.

That timeline makes it unlikely, however, that a vaccine will be available before the U.S. election, as President Donald Trump has promised. Pfizer, which is developing the vaccine with German partner BioNTech, said that it may confirm if the vaccine is effective as soon as this month but that it also needs safety data from a 44,000-person clinical trial that will not be available until next month.

The Pfizer news, published in a letter from its chief executive on its website, lifted the U.S. stock market and the company's shares. Shares fell slightly of rival vaccine maker Moderna Inc, which is close to Pfizer in its vaccine development.

"So let me be clear, assuming positive data, Pfizer will apply for Emergency Authorization Use in the U.S. soon after the safety milestone is achieved in the third week of November," Pfizer Chief Executive Albert Bourla said, noting that he published the letter to provide greater clarity on the timeline for the vaccine.

People around the world are counting on a vaccine to control the spread of the coronavirus, which has killed more than a million people and ravaged the global economy.

Fears of delays were raised after trials for two rival vaccines were put on hold in the United States in recent weeks.

Trump has said repeatedly that there would be a vaccine available before the Nov. 3 election.

When asked about the Pfizer news, White House spokesman Judd Deere said, "The president continues to be optimistic that we will have one or more vaccines very soon, before the end of the year."

The U.S. government's Operation Warp Speed program has spent billions of dollars on development of vaccines and treatments. It has signed a deal to buy Pfizer vaccine shots if they work.

But the rush to develop a vaccine has raised concerns that the U.S. Food and Drug Administration, acting in haste, might not conduct an adequate review.

U.S. health officials have sought to assuage those concerns. Earlier this month, the FDA formalized a requirement that the vaccine-makers collect two months of safety data on one-half of trial participants.

Pfizer has been trying to demonstrate that its decision-making is being driven by science rather than politics, Mizuho analyst Vamil Divan said.

"Just getting it to the market is only a small part of it," Divan said. "People should actually be willing to take it."

Rival vaccine-maker Moderna could also apply for an emergency use authorization (EUA) this year. It has said that it may have interim data on its 30,000 person trial as soon as November.

Both companies are also applying for approval in Europe, where they are racing against AstraZeneca PLC. AstraZeneca's U.S. trial has been on hold since September, while another U.S. trial of a candidate from Johnson & Johnson was paused earlier this week.

After the FDA announced the two-month requirement on Oct. 6, which was approved by the White House but undercut the likelihood of a vaccine before voters go to polls, Trump called the move a "political hit job."

In addition to safety and efficacy, the FDA will also examine Pfizer's manufacturing operations for the vaccine.

A BioNTech spokeswoman confirmed the time frame for the possible EUA application to the FDA.

Pfizer's shares were up 3.5% in afternoon trading, while BioNTech's U.S.-listed shares were up 3.9%. Moderna shares fell 1.5%.

(Reporting by Manas Mishra and Manojna Maddipatla in Bengaluru, Michael Erman in New Jersey, Patricia Weiss in Frankfurt and Alexandra Alper in Washington; writing by Caroline Humer; Editing by Steve Orlofsky and Rosalba O'Brien)

By Manas Mishra and Michael Erman

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.53% 8066 Delayed Quote.6.60%
BIONTECH SE 0.55% 94.335 Delayed Quote.177.21%
DEERE & COMPANY 1.02% 240.4 Delayed Quote.37.46%
MODERNA, INC. 2.72% 72.8 Delayed Quote.262.78%
PFIZER INC. -0.61% 37.565 Delayed Quote.-3.14%
PFIZER LIMITED 0.10% 4997.55 End-of-day quote.18.31%
share with twitter share with LinkedIn share with facebook
All news about ASTRAZENECA PLC
02:29pEXCLUSIVE : AstraZeneca U.S. COVID-19 vaccine trial may resume as soon as this w..
02:19pASTRAZENECA : U.S. COVID-19 vaccine trial may resume as soon as this week -sourc..
01:50pMexico will pay for any COVID-19 vaccine liabilities, government says
04:44aASTRAZENECA : Tagrisso granted Priority Review in the US for the adjuvant treatm..
02:39aASTRAZENECA : Granted US Priority Review for Early-Stage Lung Cancer Adjuvant Dr..
10/19France's Ose to enrol up to 400 for 'T-cell' coronavirus vaccine trials
10/19France's Ose to enroll up to 400 for 'T-cell' coronavirus vaccine trials
10/19China's Sinovac vaccine is safe, Brazil institute says
10/19Brazil's Butantan says tests show vaccine by China's Sinovac is safe
10/19ASTRAZENECA : Receives a Sell rating from Goldman Sachs
More news
Financials (USD)
Sales 2020 26 717 M - -
Net income 2020 3 074 M - -
Net Debt 2020 13 172 M - -
P/E ratio 2020 48,0x
Yield 2020 2,68%
Capitalization 138 B 138 B -
EV / Sales 2020 5,65x
EV / Sales 2021 4,93x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 118,15 $
Last Close Price 104,99 $
Spread / Highest target 48,1%
Spread / Average Target 12,5%
Spread / Lowest Target -37,1%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-1.06%379 969
ROCHE HOLDING AG-0.81%292 399
PFIZER INC.-3.14%210 050
MERCK & CO., INC.-13.50%198 975
NOVARTIS AG-14.48%190 349